Back to Journals » OncoTargets and Therapy » Volume 10

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

Total article views   Abstract views HTML views PDF downloads Totals
5,091 Dovepress* 3,550 651+ 1,311 4,201
PubMed Central* 0 890 543 890
Totals 3,550 1,541 1,854 5,091
*Since 18 January 2017
+Since July 2016

View citations on PubMed Central and Google Scholar